Effects of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies

Allan J. Paul Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.

Search for other papers by Allan J. Paul in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Douglas E. Hutchens Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.
Present address is Elanco Animal Health, Greenfield, IN 46140.

Search for other papers by Douglas E. Hutchens in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Lawrence D. Firkins Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.

Search for other papers by Lawrence D. Firkins in
Current site
Google Scholar
PubMed
Close
 DVM, MS, MBA
, and
Coleen M. Keehan Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802.
Present address is Village Animal Clinic, 25 W 510 Geneva Rd, Carol Stream, IL 60188.

Search for other papers by Coleen M. Keehan in
Current site
Google Scholar
PubMed
Close
 DVM

Abstract

Objective—To evaluate the safety of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin- sensitive Collies at dose rates of 3 to 5 times the proposed maximum therapeutic dose.

Animals—15 Collies (5 males and 10 females) that were confirmed as ivermectin-sensitive dogs.

Procedure—Dogs were assigned to 3 treatment groups (control, 3×, or 5× group) in a randomized block design on the basis of the maximal ivermectinsensitivity score obtained during preliminary screening. Dogs in groups 3× and 5× were treated at 3 and 5 times the maximum label dose, respectively. Control dogs received an application of an equal volume of a nonmedicated solution. Observation and scoring on all days were conducted to specifically include neurologic signs typical of ivermectin toxicosis, including lethargy, ataxia, abnormal mydriasis, and abnormal salivation.

Results—None of the dogs had clinical abnormalities during the study period.

Conclusions and Clinical Relevance—Analysis of results of this study indicates that dermal application of 10.0% imidacloprid-0.08% ivermectin is safe for use in ivermectin-sensitive Collies at dose rates of 3 or 5 times the proposed maximum therapeutic dose. ( Am J Vet Res 2004;65:277–278)

Abstract

Objective—To evaluate the safety of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin- sensitive Collies at dose rates of 3 to 5 times the proposed maximum therapeutic dose.

Animals—15 Collies (5 males and 10 females) that were confirmed as ivermectin-sensitive dogs.

Procedure—Dogs were assigned to 3 treatment groups (control, 3×, or 5× group) in a randomized block design on the basis of the maximal ivermectinsensitivity score obtained during preliminary screening. Dogs in groups 3× and 5× were treated at 3 and 5 times the maximum label dose, respectively. Control dogs received an application of an equal volume of a nonmedicated solution. Observation and scoring on all days were conducted to specifically include neurologic signs typical of ivermectin toxicosis, including lethargy, ataxia, abnormal mydriasis, and abnormal salivation.

Results—None of the dogs had clinical abnormalities during the study period.

Conclusions and Clinical Relevance—Analysis of results of this study indicates that dermal application of 10.0% imidacloprid-0.08% ivermectin is safe for use in ivermectin-sensitive Collies at dose rates of 3 or 5 times the proposed maximum therapeutic dose. ( Am J Vet Res 2004;65:277–278)

Advertisement